I am considering sueing GNBT for name infringement. I had a girl friend named Lyn and I used to call her Oralyn because she gave good head. Now look at her!! Hold on this One.
By way of introduction, I am a physician and healthcare executive. While I admire the attributes, both business wise as well as physical, of the wonderwoman who has shepherded Theranos to this point, there are so many holes in this whole story that I don't know where to start. In the first place, the FDA approval was granted for a HIV test to be carried out in Walgreens. This is fine from a business standpoint, since there will always be a small number of nervous people who will go to get tested for an imagined problem. This is a long way from mass testing in Africa and other places where testing is sorely needed. Now with respect to the troponin test that they report having, I can assure you that it is not FDA approved and will not be if clinical studies similar to what TRIB has done. The troponin test will never be accepted by hospitals without these clearances for obvious medicolegal reasons. Do you think that an ambulance with trained EMTs that have been called to a patient with crushing chest pain will stop by a Walgreens on the way to the ED to have a low cost troponin test done? And what if the initial test is negative? Do you repeat it in an hour or do you head on to the ER? Come on folks, have some common sense!! The medical community is not involved with the big lab companies in some devious scheme to #$%$. It costs money to make sure that the results your healthcare providers get are accurate!! Jesus!
You wouldn't go to a grocery store that didn't have price tags. Why should getting a blood test be any different? At Theranos our prices are always on-line and available. They are a fraction of other labs. And if you have insurance they are often less than the co-pay. It's all part of making lab testing as accessible as possible.
Sentiment: Strong Buy
The FDA issues 510(k) clearance for privately-held Theranos' diagnostic testing system and its test for herpes simplex 1 IgG, the 153rd test that the company provides for less than $10 in its service offering. The automated system the company has developed utilizes microfluidics to perform a wide array of tests on small volume blood samples, including those from a finger stick. Some observers believe Theranos will upend the clinical diagnostics industry with its modest costs. The herpes test, for example, will sell for only $9.07 compared to ~$175 from leading reference labs.
Sentiment: Strong Buy
Didn't you mean "We'll ?
Without tangible evidence that the funds are being deployed strategically, we are stuck with hedge-fund companies gaming the system (stock price) for their own benefit, causing pps volatility that is a distraction to management. This is not completely the hedge fund's fault, but management's inability to execute.
What does the smart money think about Trinity Biotech plc (ADR) (NASDAQ:TRIB)?
At the end of the first quarter, a total of 10 of the hedge funds we track were bullish in this stock, a change of 25% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a select group of key hedge fund managers who were upping their holdings considerably.
Of the funds we track, Richard S. Meisenberg’s ACK Asset Management had the biggest position in Trinity Biotech plc (ADR) (NASDAQ:TRIB), worth close to $10.3 million, accounting for 4.5% of its total 13F portfolio. Sitting at the No. 2 spot is Park West Asset Management, managed by Peter S. Park, which held a $7.2 million position; the fund has 0.8% of its 13F portfolio invested in the stock. Remaining peers that hold long positions include Jim Simons’s Renaissance Technologies, Chuck Royce’s Royce & Associates and Gregory Fraser, Rudolph Kluiber, and Timothy Krochuk’s GRT Capital Partners.
With a general bullishness amongst the heavyweights, key hedge funds have been driving this bullishness. ACK Asset Management, managed by Richard S. Meisenberg, established the largest position in Trinity Biotech plc (ADR) (NASDAQ:TRIB). ACK Asset Management had 10.3 million invested in the company at the end of the quarter. Israel Englander’s Millennium Management also initiated a $0.8 million position during the quarter. The other funds with new positions in the stock are Mike Vranos’s Ellington and Amy Minella’s Cardinal Capital.
How are insiders trading Trinity Biotech plc (ADR) (NASDAQ:TRIB)?
Insider buying is most useful when the company in question has seen transactions within the past 180 days. Over the latest 180-day time period, Trinity Biotech plc (ADR) (NASDAQ:TRIB) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).
Read more at http://www.insidermonkey.com/blog/this-metric-says-you-are-smart-to-buy-trinity-biotech-plc-adr-trib-175678/#kBIUX7FpRYfhMICT.99
April 30 was the last PR. This will not be viewed favorably by those who were questioning the loan. There needs to be some assurance that they have put people in place to deploy the funds to grow the company